Literature DB >> 9145719

Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease.

T J Manski1, D K Heffner, G M Glenn, N J Patronas, A T Pikus, D Katz, R Lebovics, K Sledjeski, P L Choyke, B Zbar, W M Linehan, E H Oldfield.   

Abstract

OBJECTIVES: Isolated reports suggest a possible association of endolymphatic sac tumors (ELSTs), which are extremely rare in the general population, with von Hippel-Lindau disease (VHL). To determine if hearing loss and ELSTs are a component of VHL, we examined prevalence, clinical presentation, and natural history of hearing loss and ELSTs in VHL.
DESIGN: Brain magnetic resonance images (MRIs) from 374 patients screened for VHL were reviewed for evidence of ELSTs. The VHL patients with MRI evidence suggestive of ELSTs or a history of hearing loss, tinnitus, or vertigo underwent additional radiologic and audiologic evaluations. To further assess prevalence of hearing loss and ELST in VHL, the next 66 patients screened in the VHL clinic (49 with proven VHL, 17 at risk for VHL) received MRI and audiologic assessment.
SETTING: Referral center. PARTICIPANTS: Study subjects comprised 374 persons screened for VHL, 66 consecutive patients with VHL or at risk for VHL, 4 patients with 6 ELSTs, and 13 previously reported patients with VHL and invasive tumors of the temporal bone. INTERVENTION: Magnetic resonance image and computed tomographic (CT) scan of the posterior fossa and audiologic assessment. MAIN OUTCOME MEASURES: Any ELST visible on MRI or CT and hearing loss compatible with ELST.
RESULTS: Magnetic resonance imaging revealed evidence of 15 ELSTs in 13 (11%) of 121 patients with VHL, but in none of the 253 patients without evidence of VHL (P<.001). Clinical findings in these 13 patients included hearing loss (13), tinnitus (12), vertigo (8), and facial paresis (1). Mean age at onset of hearing loss was 22 years (range, 12-50 years). Hearing for pure tones was abnormal in all affected ears and in 6 of the 11 additional, allegedly unaffected ears. In 8 patients (62%), hearing loss was the first manifestation of VHL. Presence or absence of hearing loss was associated with duration of symptoms (P<.002) and with tumor size (P<.01). Further, 43 (65%) of the 66 patients from the VHL clinic had pure tone threshold abnormalities, abnormalities that occurred bilaterally in 23 (54%) of the 43 affected subjects; however, evidence is lacking for a definitive association with ELST (3 [6%] of 49 patients with proven VHL had ELST evident on MRI).
CONCLUSIONS: Hearing loss and ELSTs are frequently associated with VHL syndrome and should be considered when screening individuals at risk for VHL and when monitoring patients with an established diagnosis of VHL. Many patients with VHL have hearing loss without radiographic evidence of an ELST. Whether it is caused by an ELST that is too small to be detected by MRI or is produced by some other etiology is still unknown. Audiologic evaluation and MRI should allow early detection and enhance management of hearing loss in these patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9145719     DOI: 10.1001/jama.277.18.1461

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  40 in total

1.  Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents.

Authors:  M T Sgambati; C Stolle; P L Choyke; M M Walther; B Zbar; W M Linehan; G M Glenn
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

2.  3p-- syndrome defines a hearing loss locus in 3p25.3.

Authors:  Brendan J McCullough; Joe C Adams; Dustin J Shilling; M Patrick Feeney; Kathleen C Y Sie; Bruce L Tempel
Journal:  Hear Res       Date:  2007-01-08       Impact factor: 3.208

3.  Neurologic manifestations of von Hippel-Lindau disease.

Authors:  John A Butman; W Marston Linehan; Russell R Lonser
Journal:  JAMA       Date:  2008-09-17       Impact factor: 56.272

4.  De novo development and progression of endolymphatic sac tumour in von hippel-lindau disease: an observational study and literature review.

Authors:  Nwaneka Eze; Alexander Huber; Bernhard Schuknecht
Journal:  J Neurol Surg B Skull Base       Date:  2013-05-28

5.  Surgical management of endolymphatic sac tumors.

Authors:  Rick A Friedman; Michael Hoa; Derald E Brackmann
Journal:  J Neurol Surg B Skull Base       Date:  2012-11-09

6.  VHL frameshift mutation as target of nonsense-mediated mRNA decay in Drosophila melanogaster and human HEK293 cell line.

Authors:  Lucia Micale; Lucia Anna Muscarella; Marco Marzulli; Bartolomeo Augello; Patrizia Tritto; Leonardo D'Agruma; Leopoldo Zelante; Gioacchino Palumbo; Giuseppe Merla
Journal:  J Biomed Biotechnol       Date:  2010-01-21

7.  Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease.

Authors:  Russell R Lonser; John A Butman; Kristin Huntoon; Ashok R Asthagiri; Tianxia Wu; Kamran D Bakhtian; Emily Y Chew; Zhengping Zhuang; W Marston Linehan; Edward H Oldfield
Journal:  J Neurosurg       Date:  2014-02-28       Impact factor: 5.115

8.  Surgical resection of endolymphatic sac tumors in von Hippel-Lindau disease: findings, results, and indications.

Authors:  H Jeffrey Kim; Marygrace Hagan; John A Butman; Martin Baggenstos; Carmen Brewer; Christopher Zalewski; W Marston Linehan; Russell R Lonser
Journal:  Laryngoscope       Date:  2012-10-15       Impact factor: 3.325

Review 9.  Update on the management of familial central nervous system tumor syndromes.

Authors:  Andreas F Hottinger; Yasmin Khakoo
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

10.  Improved detection of germline mutations in Korean VHL patients by multiple ligation-dependent probe amplification analysis.

Authors:  Hyun-Jung Cho; Chang-Seok Ki; Jong-Won Kim
Journal:  J Korean Med Sci       Date:  2009-02-28       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.